[ Back to EurekAlert! ]

Contact: Bill Schaller
Dana-Farber Cancer Institute

Andrea Richardson, M.D., Ph.D, Dana-Farber Cancer Institute

Caption: Andrea Richardson, M.D., Ph.D, and her colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Credit: Sam Ogden

Usage Restrictions: None

Related news release: DNA marker predicts platinum drug response in breast, ovarian cancer

[ Back to EurekAlert! ]